Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Daily Utah.
Press releases published on April 18, 2025
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
April 18, 2025
SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL …
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
GlobeNewswire
·
April 18, 2025
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License …
AMMO, Inc. Completes Sale of Ammunition Manufacturing Assets to Olin Winchester
GlobeNewswire
·
April 18, 2025
Sale Transitions AMMO to an E-commerce-Focused Company Accelerating Growth Through GunBroker.com, the Largest Online Marketplace for Firearms, Hunting and Related Products Sale Allows Company to Center its Attention on Innovation, Profitability, and Long- …
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
GlobeNewswire
·
April 18, 2025
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite …
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
GlobeNewswire
·
April 18, 2025
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more …
Communiqué de presse : Le Dupixent devient le premier nouveau médicament ciblé approuvé aux États-Unis depuis plus de dix ans pour le traitement de l’urticaire chronique spontanée
GlobeNewswire
·
April 18, 2025
Le Dupixent devient le premier nouveau médicament ciblé approuvé aux États-Unis depuis plus de dix ans pour le traitement de l’urticaire chronique spontanée Aux États-Unis, le Dupixent est indiqué à plus de 300 000 adultes et adolescents âgés de 12 ans et …
ASUS Introduces Upgraded TUF Gaming A14 for Ultimate Performance
GlobeNewswire
·
April 18, 2025
TORONTO, April 18, 2025 (GLOBE NEWSWIRE) -- ASUS today announced an all-new ASUS TUF Gaming A14 equipped with an AMD Ryzen™ AI 7 350 CPU and an NVIDIA® GeForce RTX™ 5060 Laptop GPU. Housed in an incredibly portable and lightweight 14-inch form factor …
Surfshark turns 7 and offers users a special birthday deal
GlobeNewswire
·
April 18, 2025
Leading cybersecurity company Surfshark is celebrating its 7th anniversary. For that occasion, it offers users a limited-time birthday deal. As part of its birthday celebration, Surfshark is offering special pricing across its suite of privacy plans (until …
NordVPN’s travel eSIM app, Saily, preserves nearly 30% of mobile data, independent audit confirms
GlobeNewswire
·
April 18, 2025
LONDON, April 18, 2025 (GLOBE NEWSWIRE) -- Saily, a travel eSIM app by the company behind NordVPN, has just completed third party testing of its ad blocker technology benefits. The test performed by West Coast Labs, a leading independent testing lab, …
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
GlobeNewswire
·
April 18, 2025
CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it …
NordPass wins at Global Tech Awards 2025 for excellence in Cyber Security Technology category
GlobeNewswire
·
April 18, 2025
LONDON, April 18, 2025 (GLOBE NEWSWIRE) -- NordPass, a leading password manager developed by the cybersecurity experts behind NordVPN, has been named a winner in the Cyber Security Technology (CyberTech) category at the Global Tech Awards 2025. The …
Best Accounting Software for Freelancers (2025): QuickBooks Named Top Accounting Software by Software Experts
GlobeNewswire
·
April 18, 2025
NEW YORK CITY, April 18, 2025 (GLOBE NEWSWIRE) -- Software Experts has named QuickBooks as the Best Accounting Software for Freelancers in its annual review of tools tailored for independent professionals. The recognition highlights QuickBooks’ …
FARO to Announce Financial Results for the First Quarter 2025 on April 24, 2025
GlobeNewswire
·
April 18, 2025
LAKE MARY, Fla., April 18, 2025 (GLOBE NEWSWIRE) -- FARO® Technologies, Inc. (Nasdaq: FARO), a global leader in 4D digital reality solutions, today announced that before market open on Thursday, April 24, 2025, it will release its financial results for the …
JuicyChat.AI Redefines NSFW AI Anime Ecosystem, Closes Loop for Creators
GlobeNewswire
·
April 18, 2025
NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- JuicyChat.AI is redefining the landscape of NSFW AI-powered anime content with a groundbreaking ecosystem that prioritizes NSFW AI creators and their core needs. With a vision to build a closed-loop creation …
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
GlobeNewswire
·
April 18, 2025
Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory …
Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya
GlobeNewswire
·
April 18, 2025
Saint-Herblain (France), le 18 avril 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que lors de sa réunion ordinaire du 16 avril 2025, le comité consultatif américain sur les pratiques …